. Author manuscript; available in PMC: 2010 Jun 1.

Published in final edited form as: Exp Mol Pathol. 2009 Jan 20;86(3):151–164. doi: 10.1016/j.yexmp.2009.01.004

Table 1. Cancer Cell Lines that are Responsive to AS1411 or GRO29A.

CANCER TYPE	CELL LINES
Lung Cancer	A549^a^,^f, NCI-H322M^a, NCI-H460^a, EKVX^a, HOP-92^b, NCI-H299^c, CaLu1^c, NCI-H1385^c, NCI-H82^c, CaLu6^e
Breast Cancer	MCF7^a^,^f, T-47D^a, BT-549^b, MDA-N^b, MDA-MB-231^b^,^f, ZR7S-1^e
Prostate Cancer	DU145^a^,^f, PC-3^b, CA-HPV-10^c
Colon Cancer	HCC 2998^a, HT-29^a, KM12^a, HCT-116^b, SW620^b, HCT-15^b, LS174T^e
Pancreatic Cancer	PANC-1^c, MIA-PaCa-2^c, PANC-1^e
Renal Cell Carcinoma	786-0^a, CAKI-1^a, RXF393^a, TK10^a, A498^b, ACHN^b, SN12C^b
Ovarian Cancer	IGROV1^b, OVCAR-3^b, OVCAR-4^b, OVCAR-5^b
Cervical Cancer	HeLa^c^,^f
Leukemia and Lymphoma	CCRF-CEM^a, SR^a, HL60^b, K-562^b, RPMI-6226^b, U937^c, Meg01^c, MV4-11^e
Melanoma	LOX-IMVI^b, SK-MEL-2^b, A375^c, SK-MEL-28^e, MDA-MB-435^b^,^g
Glioblastoma	SF-268^a, U87-MG^e
Neuroblastoma	IMR 32^c^,^d, Lan 5^c^,^d
Sarcoma	HT-1080^c
Gastric Cancer	KATOIII^e, HGC27^e

Data from NCI Tumor Cell Line Screen of AS1411 (≥ 50% growth inhibition at 6.3 μM).

Data from NCI Tumor Cell Line Screen of AS1411 (30-49 % growth inhibition at 6.3 μM).

Bates, Miller, Thomas, et al., unpublished data using AS1411 or GRO29A.

In collaboration with Thomas H. Inge.

Data reported by Antisoma (see reference 171).

Reported previously for AS1411 or GRO29A (see references 25-31).

This line was previously believed to be derived from breast cancer.